Northwest & Ethical Investments L.P. Has $1.67 Million Stock Holdings in United Therapeutics Corporation $UTHR

Key Points

• Northwest & Ethical Investments L.P. increased its stake in United Therapeutics by 42% during the first quarter, now owning 5,416 shares valued at approximately $1.67 million.
• Multiple institutional investors including Vanguard Group Inc. and AQR Capital Management LLC also boosted their holdings, indicating strong interest in United Therapeutics.
• United Therapeutics reported a miss in earnings with $6.41 per share against a consensus of $6.80, while revenue increased 11.7% year-over-year, totaling $798.6 million.

Northwest & Ethical Investments L.P. grew its stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 42.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,416 shares of the biotechnology company's stock after buying an additional 1,602 shares during the quarter. Northwest & Ethical Investments L.P.'s holdings in United Therapeutics were worth $1,670,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Hohimer Wealth Management LLC raised its holdings in shares of United Therapeutics by 0.3% during the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after acquiring an additional 37 shares during the period. Applied Finance Capital Management LLC raised its holdings in shares of United Therapeutics by 3.7% during the first quarter. Applied Finance Capital Management LLC now owns 1,132 shares of the biotechnology company's stock valued at $349,000 after acquiring an additional 40 shares during the period. Headlands Technologies LLC raised its holdings in shares of United Therapeutics by 1.5% during the first quarter. Headlands Technologies LLC now owns 2,687 shares of the biotechnology company's stock valued at $828,000 after acquiring an additional 40 shares during the period. Dunhill Financial LLC raised its holdings in shares of United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after acquiring an additional 50 shares during the period. Finally, Callan Family Office LLC raised its holdings in shares of United Therapeutics by 5.4% during the first quarter. Callan Family Office LLC now owns 968 shares of the biotechnology company's stock valued at $298,000 after acquiring an additional 50 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Activity at United Therapeutics

In related news, Director Richard Giltner sold 3,036 shares of the company's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $289.60, for a total transaction of $879,225.60. Following the completion of the transaction, the director directly owned 19,384 shares in the company, valued at $5,613,606.40. This represents a 13.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 12,000 shares of the company's stock in a transaction on Monday, June 9th. The shares were sold at an average price of $325.37, for a total transaction of $3,904,440.00. Following the transaction, the chief financial officer owned 8,118 shares of the company's stock, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 92,681 shares of company stock valued at $28,014,609 in the last 90 days. 10.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on UTHR shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of United Therapeutics in a research report on Thursday, August 14th. UBS Group boosted their price objective on shares of United Therapeutics from $385.00 to $415.00 and gave the company a "buy" rating in a research report on Wednesday, August 13th. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. HC Wainwright set a $400.00 price objective on shares of United Therapeutics and gave the company a "buy" rating in a research report on Thursday, July 31st. Finally, Bank of America lowered their price objective on shares of United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research report on Wednesday, June 11th. Nine analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $382.00.

United Therapeutics Stock Performance

Shares of United Therapeutics stock traded up $1.57 on Friday, reaching $312.23. The stock had a trading volume of 576,473 shares, compared to its average volume of 525,026. The business's 50-day moving average price is $296.44 and its two-hundred day moving average price is $307.95. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The stock has a market cap of $14.08 billion, a P/E ratio of 12.19, a price-to-earnings-growth ratio of 4.64 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm had revenue of $798.60 million during the quarter, compared to analyst estimates of $802.13 million. During the same quarter in the previous year, the firm posted $5.85 earnings per share. United Therapeutics's quarterly revenue was up 11.7% compared to the same quarter last year. As a group, equities analysts forecast that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.